DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)

NCT ID: NCT04709705

Last Updated: 2025-10-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 161 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-27
• Study Completion Date: 2025-05-08

Brief Summary

A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery.

Detailed Description

A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery. Patients planning to undergo Cardiopulmonary Bypass Surgery with risk factors for significant bleeding post-surgery will be approached. Subjects will be randomized in a 1:1 ratio to receive either Cryopreserved Platelets or Liquid Stored Platelets. Eligible subjects will undergo Cardiopulmonary Bypass Surgery and at the completion of bypass and heparin reversal subjects will likely be assessed for eligibility before coming off bypass. Study platelets will be given either intraoperatively after heparin reversal and return of active clotting time (ACT) to < 140 sec or post operatively (after chest closure).

A single unblinded interim analysis on the primary efficacy endpoint will be performed for this study after 75% of the planned number of mITT subjects are treated (i.e., after 150 mITT subjects are treated, irrespective of the number of subjects in each treatment group).

Conditions

Cardiac Surgery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Cryopreserved platelets

Cryopreserved platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal

Group Type: EXPERIMENTAL

Human platelets

Intervention Type: BIOLOGICAL

Platelets given to control bleeding

Liquid stored platelets

Liquid stored platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal

Group Type: ACTIVE_COMPARATOR

Human platelets

Intervention Type: BIOLOGICAL

Platelets given to control bleeding

Interventions

Human platelets

Platelets given to control bleeding

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female, at least 18 years of age

2. Undergoing CPB surgery with at least one risk factor for post-surgical bleeding including:

1. All re-operative cardiac procedures.

2. Expected bypass > 120 minutes.

3. Any combined cardiac surgery procedures (e.g. multiple valve, valve/CABG).

4. Any procedure that in the estimation of the surgical attending, has a high likelihood of receiving platelets

3. Ability to comprehend and willingness to sign informed consent.

4. If female of childbearing potential, have a negative pregnancy test on the day of the surgery and prior to the surgery agrees to use a method of highly effective birth control from the time of consent through the end of the safety follow-up period (Day 6 or discharge from hospital, whichever is earlier). Note: women must have been surgically sterilized [bilateral tubal ligation, bilateral oophorectomy, total hysterectomy) or postmenopausal (≥50 years of age and continuous amenorrhea for 24 months) to be considered non-childbearing potential.

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from the study:

1. Undergoing any of the following surgical procedures:

1. Coronary artery bypass surgery alone

2. Implantation of ventricular assist device

3. Thoracoabdominal aortic aneurysm repair

2. Known or suspected pregnancy or breastfeeding

3. History of any major unprovoked thrombotic events

4. History of heparin-inducted thrombocytopenia

5. Active infection treated with antibiotics

6. Refuse transfusion of blood products for religious or other reasons

7. Previous enrollment in this study

8. Immune thrombocytopenic purpura

9. Known allergy to DMSO

10. In the judgement of the investigator, is not a good candidate for the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

U.S. Army Medical Research and Development Command

FED

Sponsor Role: collaborator

Cellphire Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Alabama

Birmingham, Alabama, United States

University of Colorado

Aurora, Colorado, United States

George Washington University

Washington D.C., District of Columbia, United States

UF Health

Gainesville, Florida, United States

Maine Medical Center

Portland, Maine, United States

University of Maryland Medical Center

Baltimore, Maryland, United States

Johns Hopkins University

Baltimore, Maryland, United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Duke University Hospital

Durham, North Carolina, United States

The Ohio State Univ. Wexner Medical Center

Columbus, Ohio, United States

OU Medical Center

Oklahoma City, Oklahoma, United States

Oregon Health and Science University

Portland, Oregon, United States

Abington Memorial Hospital

Abington, Pennsylvania, United States

Thomas Jefferson Univ. Hospital

Philadelphia, Pennsylvania, United States

University of Virginia Medical Center

Charlottesville, Virginia, United States

Inova Cardiac Vascular

Falls Church, Virginia, United States

Countries

United States

Other Identifiers

S-16-15

Identifier Type: -

Identifier Source: org_study_id